Abstract Session 7

Co-Chair(s)

• 

  Damian Green, MD (he/him/his)

  Chief, Division of Transplantation and Cellular Therapy
  Sylvester Comprehensive Cancer Center/University of Miami
  Miami, Florida
• MA

  Melissa Alsina, MD (she/her/hers)

  Head, Myeloma Section, BMT-CI Program
  H. Lee Moffitt Cancer Center
  Tampa, Florida

Presentations:

• 08:00 - 08:10 East Coast USA Time

  (OA-50) Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from the CC-220-MM-001 Trial
  

  Abstract Presenter: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
• 08:10 - 08:20 East Coast USA Time

  (OA-46) Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022-05)
  

  Abstract Presenter: Arthur F. Bobin (he/him/his) – University Hospital of Poitiers
• 08:20 - 08:30 East Coast USA Time

  (OA-48) Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide
  

  Abstract Presenter: Verónica González-Calle, MD, PhD (she/her/hers) – Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC)
• 08:30 - 08:40 East Coast USA Time

  (OA-47) Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
  

  Abstract Presenter: Larry D. Anderson, Jr., MD, PhD (he/him/his) – Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
• 08:40 - 08:50 East Coast USA Time

  (OA-51) Carfilzomib, Lenalidomide, and Dexamethasone (KRd) after Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Analysis of High-Risk Subset in Phase 3 ATLAS Trial
  

  Abstract Presenter: Andrzej Jakubowiak, MD, PhD – The University of Chicago